Look behind the lecture: reimbursing innovative and potentially curative gene and cell therapies

In this feature, following his participation in a workshop at the International Society for Pharmacoeconomics and Outcomes Research’s 2020 Asia Pacific meeting (Virtual ISPOR Asia Pacific 2020; 14–16 September), Sean Sullivan (University of Washington, WA, USA) discusses payment approaches that could potentially help better manage the market entry of innovative and potentially curative therapies, despite uncertainties surrounding their long-term benefits. Please could you introduce yourself and give a brief overview of your presentation at Virtual ISPOR Asia Pacific 2020? I am a Professor at the University of Washington (WA, USA) and Dean of the university’s School of Pharmacy. I trained...